Market Uptake Of New Incontinence Agents Impeded By Efficacy Perceptions, Novartis Says
Public may view new overactive bladder treatments, such as Novartis' Enablex, as lacking efficacy advantages, according to the company.
Public may view new overactive bladder treatments, such as Novartis' Enablex, as lacking efficacy advantages, according to the company.